glutamic acid has been researched along with Depressive Disorder, Treatment-Resistant in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 11 (73.33) | 24.3611 |
| 2020's | 4 (26.67) | 2.80 |
| Authors | Studies |
|---|---|
| Camargo, A; Rodrigues, ALS | 1 |
| Brown, EC; Clark, DL; Kiss, ZHT; MacMaster, FP; Ramasubbu, R | 1 |
| Armant, RJ; Bolaños-Guzmán, CA; Kokane, SS; Perrotti, LI | 1 |
| Coombes, BJ; Frye, MA; Geske, JR; Lanza, IR; Morgan, RJ; Port, JD; Singh, B; Voort, JLV | 1 |
| Ballard, ED; Farmer, C; Henn, FA; Henter, ID; Kadriu, B; Lener, MS; Niciu, MJ; Nugent, AC; Park, LT; Park, M; Yazdian, A; Yuan, S; Zarate, CA | 1 |
| Bai, YM; Chen, MH; Huang, MH; Li, CT; Liu, RS; Su, TP; Tu, PC; Yang, BH | 1 |
| An, L; Banerjee, D; Evans, JW; Lally, N; Li, N; Nugent, AC; Roiser, JP; Shen, J; Snider, SL; Zarate, CA | 1 |
| Adell, A; Auberson, YP; Campa, L; Jiménez-Sánchez, L | 1 |
| Abdallah, CG; Duman, RS; Krystal, JH; Sanacora, G | 1 |
| Hall, BJ; Miller, OH; Moran, JT | 1 |
| Chen, MH; Hong, CJ; Li, CT; Lin, WC; Liu, RS; Su, TP; Tu, PC; Yang, BH | 1 |
| Bottrel, N; Corum, DG; Drevets, WC; Fiehn, O; Kaddurah-Daouk, R; Motsinger-Reif, A; Rotroff, DM; Salvadore, G; Singh, J | 1 |
| Harris, AD; Jasaui, Y; Jaworska, N; Kirton, A; Langevin, LM; Lebel, RM; Lefebvre, D; MacMaster, FP; Sembo, M; Swansburg, R; Wilkes, TC | 1 |
| Bernabéu-Sanz, Á; Cano, M; Cardoner, N; Contreras-Rodríguez, O; de Arriba-Arnau, A; Gálvez, V; Hernández-Ribas, R; Martínez-Zalacaín, I; Menchón, JM; Pujol, J; Soriano-Mas, C; Urretavizcaya, M; Via, E | 1 |
| Andree, TH; Bender, CN; Brennan, J; Dunlop, J; Dwyer, JM; Harrison, JE; Hughes, ZA; Kouranova, E; Leonard, SK; Lotarski, S; Lu, S; Neal, SJ; O'Neil, SV; Olsen, M; Pulicicchio, CM; Ring, RH; Rosenzweig-Lipson, S; Schechter, LE; Smith, DL; Springer, D; Sukoff Rizzo, SJ; Whiteside, GT | 1 |
4 review(s) available for glutamic acid and Depressive Disorder, Treatment-Resistant
| Article | Year |
|---|---|
Guanosine as a promising target for fast-acting antidepressant responses.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Glutamic Acid; Guanosine; Humans; Ketamine | 2022 |
Overlap in the neural circuitry and molecular mechanisms underlying ketamine abuse and its use as an antidepressant.
Topics: Antidepressive Agents; Brain; Cholinergic Neurons; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Excitatory Amino Acid Antagonists; GABA Agents; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Ketamine; Neural Pathways; Norepinephrine; Receptors, GABA-A; Receptors, N-Methyl-D-Aspartate; Serotonin; Substance-Related Disorders | 2020 |
Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics.
Topics: Antidepressive Agents; Brain; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Excitatory Amino Acid Antagonists; Glutamic Acid; Humans; Ketamine; Mood Disorders; Neuronal Plasticity; Prefrontal Cortex | 2015 |
Two cellular hypotheses explaining the initiation of ketamine's antidepressant actions: Direct inhibition and disinhibition.
Topics: Animals; Antidepressive Agents; Brain; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Electroconvulsive Therapy; Excitatory Amino Acid Antagonists; Glutamic Acid; Humans; Interneurons; Ketamine; Models, Neurological; Neural Inhibition; Neuronal Plasticity; Neurons; Protein Subunits; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate | 2016 |
3 trial(s) available for glutamic acid and Depressive Disorder, Treatment-Resistant
| Article | Year |
|---|---|
Clinical Trial of the Potassium Channel Activator Diazoxide for Major Depressive Disorder Halted Due to Intolerability.
Topics: Adult; Aged; Cross-Over Studies; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Diazoxide; Dose-Response Relationship, Drug; Double-Blind Method; Early Termination of Clinical Trials; Female; Glutamic Acid; Humans; Male; Middle Aged; Potassium Channels; Psychiatric Status Rating Scales; Treatment Outcome | 2018 |
7T
Topics: Adult; Antidepressive Agents; Brain; Cross-Over Studies; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Female; Glutamic Acid; Glutamine; Humans; Ketamine; Male; Proton Magnetic Resonance Spectroscopy | 2018 |
The effects of low-dose ketamine on the prefrontal cortex and amygdala in treatment-resistant depression: A randomized controlled study.
Topics: Adult; Amygdala; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Dose-Response Relationship, Drug; Double-Blind Method; Excitatory Amino Acid Antagonists; Female; Fluorodeoxyglucose F18; Glutamic Acid; Humans; Ketamine; Linear Models; Male; Middle Aged; Positron-Emission Tomography; Prefrontal Cortex; Psychiatric Status Rating Scales; Radiopharmaceuticals | 2016 |
8 other study(ies) available for glutamic acid and Depressive Disorder, Treatment-Resistant
| Article | Year |
|---|---|
Rostral anterior cingulate glutamate predicts response to subcallosal deep brain stimulation for resistant depression.
Topics: Adult; Deep Brain Stimulation; Depressive Disorder, Treatment-Resistant; Glutamic Acid; Gyrus Cinguli; Humans; Treatment Outcome | 2020 |
A preliminary study of the association of increased anterior cingulate gamma-aminobutyric acid with remission of depression after ketamine administration.
Topics: Depression; Depressive Disorder, Treatment-Resistant; gamma-Aminobutyric Acid; Glutamic Acid; Gyrus Cinguli; Humans; Ketamine | 2021 |
Elevated tumor necrosis factor-alpha receptor subtype 1 and the association with abnormal brain function in treatment-resistant depression.
Topics: Adult; Brain; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Female; Glutamic Acid; Gyrus Cinguli; Humans; Male; Middle Aged; Positron-Emission Tomography; Receptors, Tumor Necrosis Factor, Type I | 2018 |
The role of GluN2A and GluN2B subunits on the effects of NMDA receptor antagonists in modeling schizophrenia and treating refractory depression.
Topics: Animals; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Disease Models, Animal; Dizocilpine Maleate; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Glutamic Acid; Male; Phenols; Piperidines; Prefrontal Cortex; Quinoxalines; Rats, Wistar; Receptors, N-Methyl-D-Aspartate; Schizophrenia; Serotonin; Stereotyped Behavior | 2014 |
Metabolomic signatures of drug response phenotypes for ketamine and esketamine in subjects with refractory major depressive disorder: new mechanistic insights for rapid acting antidepressants.
Topics: Adult; Arginine; Citrulline; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Excitatory Amino Acid Antagonists; Female; Glutamic Acid; Humans; Indoleacetic Acids; Infusions, Intravenous; Ketamine; Male; Metabolomics; Methionine; Middle Aged; Ornithine; Phenotype; Phospholipids; Tryptophan; Urea | 2016 |
A pilot study of hippocampal N-acetyl-aspartate in youth with treatment resistant major depression.
Topics: Adolescent; Aspartic Acid; Brain; Case-Control Studies; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Female; Glutamic Acid; Hippocampus; Humans; Magnetic Resonance Imaging; Male; Pilot Projects; Proton Magnetic Resonance Spectroscopy; Young Adult | 2017 |
Brain volumetric and metabolic correlates of electroconvulsive therapy for treatment-resistant depression: a longitudinal neuroimaging study.
Topics: Aged; Aspartic Acid; Brain; Case-Control Studies; Depressive Disorder, Treatment-Resistant; Electroconvulsive Therapy; Female; Glutamic Acid; Glutamine; Gyrus Cinguli; Hippocampus; Humans; Imaging, Three-Dimensional; Magnetic Resonance Imaging; Male; Middle Aged; Organ Size; Proton Magnetic Resonance Spectroscopy; Temporal Lobe | 2017 |
Negative allosteric modulation of metabotropic glutamate receptor 5 results in broad spectrum activity relevant to treatment resistant depression.
Topics: Allosteric Regulation; Analgesics; Animals; Anti-Anxiety Agents; Antidepressive Agents; Behavior, Animal; Benzamides; Calcium; Depressive Disorder, Treatment-Resistant; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Excitatory Amino Acid Antagonists; Glutamic Acid; HEK293 Cells; Humans; Mice; Pyridines; Radioligand Assay; Rats; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate | 2013 |